iPSC来源的心肌细胞团移植在非人灵长类模型中改善心梗后心脏功能
Cell therapy using cardiac muscle cell aggregates improves heart function following a heart attack
德国格廷根灵长类研究中心与汉诺威医学院合作,在食蟹猴心梗模型中注射由人诱导多能干细胞(hiPSC)制备的心肌细胞聚集体(hiCMAs)。3个月时出现新的人类心肌纤维,心脏功能改善,但存在短暂心律失常。研究发表于Nature Communications,DOI 10.1038/s41467-026-77103-0。
非人灵长类模型显示移植细胞团可改善心功能,为干细胞治疗心梗提供临床前依据。
In the event of a heart attack, the affected part of the heart muscle can no longer be supplied with oxygen and nutrients. As a result, the heart muscle cells (cardiomyocytes) die off. Scar tissue forms, and heart function is impaired. This often leads to chronic heart failure—also known in medical terms as cardiac insufficiency. It is one of the most common causes of death in the Western world.
Dr. Ulrich Martin, head of the Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO) at Hanover Medical School (MHH), and Dr. Robert Zweigerdt, a cell biologist at LEBAO, aim to repair the damaged areas of the heart using biotechnologically produced heart muscle cells. They are not relying on individual cells, but on small clusters of human cardiomyocytes, which are produced in large quantities and injected directly into the heart muscle.
They have now investigated this therapeutic concept in collaboration with and at the German Primate Centre in Göttingen, using a model of heart attack in Javanese macaques. The preclinical study showed that the treatment improved heart function after three months. The results have been published in the journal Nature Communications.
Cell aggregates form extensive muscle fibers in the heart
The researchers and their team used human induced pluripotent stem cells (hiPSCs). These can be produced in the laboratory from "reprogrammed" somatic cells, such as blood cells, and can then give rise to any cell type in the human body—including cardiac muscle cells. The biotechnologically derived cardiac muscle cells develop into spherical cell aggregates while still being produced in the laboratory in special bioreactors. The assumption is that, compared with individual cells, more of these aggregates remain in the heart and integrate better into the heart muscle.
In the current study, the researchers injected hiPSC-derived cardiac muscle cell aggregates (hiCMAs) into the hearts of primates in which a heart attack had previously been induced. Three months after the procedure, extensive new human cardiac muscle fibers had formed. Although the cell transplant led to temporary cardiac arrhythmias, it had positive effects on heart function over time.
hiPSCs have their own heart rate
There is a reason why the experiments were carried out on monkeys rather than, for example, mice. While mice and rats are, in principle, suitable for many other animal studies, preclinical testing of this cell therapy concept cannot be carried out in small animal models. This is because their hearts are much smaller and also have a significantly higher heart rate than those of humans.
"This would not be compatible with human cardiac muscle cells, which have their own human heart rate, meaning that observations made here do not allow any conclusions to be drawn about humans," explains Zweigerdt. In large animal models, such as pigs, the heart is much more similar to that of humans in terms of size and metabolic processes, including heart rate. However, the animal's immune system immediately recognizes the human cells as foreign and rejects them. In monkey hearts, by contrast, the human donor cells can grow and survive largely without difficulty with appropriate immunosuppressive medication.
In their studies, the researchers tested hiCMAs from two different iPSC lines. "We found that only cardiac muscle cells from one of the two lines had a positive effect on heart function, even though both lines resulted in human grafts of similar size in the monkey heart," notes Zweigerdt. "Our study suggests that the contraction of cardiac muscle cells in cell culture is linked to their potential to improve cardiac function. It is therefore important to examine the function of the cell aggregates, including their contractile force, prior to transplantation."
Long-term therapies using the body's own cells
There are already a number of ongoing clinical trials worldwide into therapies using cultured heart muscle cells. However, the stem cells used in these trials were not derived from the patient's own cells, but from donor cells. The problem is that, as with a donor organ, the immune response following cell transplantation must be suppressed with medication for the rest of the patient's life. This poses a further risk and limits the number of patients who could benefit from cell therapy using cardiac muscle cells.
The MHH scientists are therefore pursuing a different long-term approach. They aim to transplant hiCMAs derived from the patients' own, so-called autologous, blood cells. "A major advantage of this is that no immunosuppression—which is associated with side effects—is required," notes Martin. This could lead to greater acceptance, particularly among younger patients, and accelerate the development of the therapy despite higher costs.
Research into stem cell therapy
For more than 20 years, Martin and Zweigerdt, together with their team, have been working on the development of cell therapies to treat severe heart conditions. As part of the iCARE project, the researchers have already demonstrated in animal models that the cell aggregates integrate into heart tissue and improve organ function. In the HEAL research project, they aim to refine the strategies for producing and administering the hiCM aggregates so that they can be used for cardiac therapy in humans.
"Living cells are an extremely complex medicine," emphasizes Martin. "While we cannot completely heal a pre-damaged heart with them, we can give it a sort of 'fresh cell treatment' that could improve its function in the long term."
However, before this therapy becomes part of standard care, it will still need to be tested in clinical trials for safety and tolerability. Yet the researchers are optimistic. In their new project, iNDUCARE, they are already working on the prerequisites to make the complex production of the necessary autologous iPSCs simpler, faster and more cost-effective.
Publication details
Ina Gruh et al., Human iPSC-cardiomyocyte-aggregate cell therapy in non-human primates and correlation of heart recovery with contractile and electrophysiological cardiomyocyte properties, Nature Communications (2026). DOI: 10.1038/s41467-026-77103-0
Journal information: Nature Communications
Key medical concepts
Clinical categories
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Cell therapy using cardiac muscle cell aggregates improves heart function following a heart attack (2026, October 20) retrieved 20 October 2026 from https://medicalxpress.com/news/2026-10-cell-therapy-cardiac-muscle-aggregates.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com